Dr. Robert L. Coleman, M.D.
Gynecologic Oncology (Gynecologic Oncology Physician)
At a glance
- Medical school
- Creighton University School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
Licensed in Texas since 1992, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Creighton University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
TX license J0933 (first issued 1992; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 17 companies reported 107 payments worth $136,279 in total to this clinician.
| Merck Sharp & Dohme LLC | $41,752 |
|---|---|
| GlaxoSmithKline, LLC. | $25,443 |
| Eisai Inc. | $9,779 |
| Corcept Therapeutics | $8,171 |
| Regeneron Pharmaceuticals, Inc. | $8,157 |
| AstraZeneca Pharmaceuticals LP | $6,318 |
| AstraZeneca UK Limited | $6,158 |
| Aadi Bioscience, Inc. | $5,808 |
| Consulting Fee | $81,182 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $28,569 |
| Travel and Lodging | $23,604 |
| Food and Beverage | $2,881 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging travel to Sao Paulo, Brazil · in-kind | $9,809 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Merck Sharp & Dohme LLC Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| GlaxoSmithKline, LLC. Aug 18, 2025 | Consulting Fee | $7,200 |
| GlaxoSmithKline, LLC. Mar 19, 2025 | Consulting Fee | $7,200 |
| Corcept Therapeutics May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,600 |
| Merck Sharp & Dohme LLC Sep 25, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Lima, Peru · in-kind | $5,564 |
| Eisai Inc. May 1, 2025 | Consulting Fee Lenvima · Oncology | $4,890 |
| AstraZeneca UK Limited Jul 29, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,510 |
| Merck Sharp & Dohme LLC Dec 17, 2025 | Consulting Fee | $3,840 |
All 64 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Aadi Bioscience, Inc. Dec 19, 2025 | Consulting Fee Fyarro · Oncology | $2,550 |
| Merck Sharp & Dohme LLC Dec 17, 2025 | Consulting Fee | $3,840 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Consulting Fee | $2,880 |
| Beone Medicines USA, Inc. Dec 2, 2025 | Consulting Fee | $1,600 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| Gilead Sciences, Inc. Nov 21, 2025 | Consulting FeeCompany’s description;4212705;GTF;10845904 | $3,790 |
| GlaxoSmithKline, LLC. Nov 21, 2025 | Consulting Fee | $1,600 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $915 |
| Aadi Bioscience, Inc. Nov 14, 2025 | Consulting Fee Fyarro · Cancer | $1,983 |
| Incyte Corporation Nov 14, 2025 | Consulting Fee | $1,035 |
| AstraZeneca Pharmaceuticals LP Oct 24, 2025 | Consulting Fee LYNPARZA · Oncology | $1,370 |
| Corcept Therapeutics Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,400 |
| Gilead Sciences, Inc. Oct 17, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind Company’s description;4212680;GTF;10845904 | $57.39 |
| Merck Sharp & Dohme LLC Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Eisai Inc. Oct 1, 2025 | Consulting Fee Lenvima · Oncology | $2,036 |
| Merck Sharp & Dohme LLC Oct 1, 2025 | Travel and Lodging travel to Lima, Peru | $150 |
| Merck Sharp & Dohme LLC Sep 25, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Lima, Peru · in-kind | $5,564 |
| Merck Sharp & Dohme LLC Sep 25, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Lima, Peru · in-kind | $243 |
| EMD Serono Research & Development Institute, Inc. Sep 24, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $2,700 |
| Merck Sharp & Dohme LLC Sep 24, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Lima, Peru · in-kind | $243 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Lima, Peru · in-kind | $243 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Lima, Peru · in-kind | $152 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Lima, Peru · in-kind | $44.97 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Travel and Lodging travel to Sao Paulo, Brazil | $150 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging travel to Sao Paulo, Brazil · in-kind | $9,809 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging travel to Sao Paulo, Brazil · in-kind | $295 |
| Merck Sharp & Dohme LLC Sep 11, 2025 | Travel and Lodging travel to Sao Paulo, Brazil · in-kind | $116 |
| Aadi Bioscience, Inc. Sep 9, 2025 | Consulting Fee Fyarro · Oncology | $1,275 |
| AstraZeneca Pharmaceuticals LP Aug 21, 2025 | Consulting Fee | $1,370 |
| Daiichi Sankyo Inc. Aug 21, 2025 | Travel and Lodging Enhertu · ONCOLOGY · travel to MIAMI, FL · in-kind | $88.67 |
| GlaxoSmithKline, LLC. Aug 18, 2025 | Consulting Fee | $7,200 |
| AstraZeneca UK Limited Aug 11, 2025 | Travel and Lodging travel to Gaithersburg and Virtual, MD Company’s descriptionResearch Related Service | $1,177 |
| AstraZeneca UK Limited Aug 11, 2025 | Travel and Lodging travel to Gaithersburg and Virtual, MD Company’s descriptionResearch Related Service | $336 |
| AstraZeneca UK Limited Jul 29, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $4,510 |
| GlaxoSmithKline, LLC. Jul 23, 2025 | Consulting Fee | $2,400 |
| GlaxoSmithKline, LLC. Jul 10, 2025 | Consulting Fee | $1,600 |
| Beone Medicines USA, Inc. Jul 9, 2025 | Consulting Fee | $2,400 |
| Merck Sharp & Dohme LLC Jun 16, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $939 |
| Eisai Inc. Jun 11, 2025 | Consulting Fee Lenvima · Oncology | $2,853 |
| AstraZeneca Pharmaceuticals LP Jun 11, 2025 | Consulting Fee | $2,050 |
| AstraZeneca Pharmaceuticals LP Jun 2, 2025 | Consulting Fee | $1,370 |
| Corcept Therapeutics May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,600 |
| GlaxoSmithKline, LLC. May 20, 2025 | Consulting Fee | $800 |
| Regeneron Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee | $3,268 |
| Regeneron Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee | $1,634 |
| Eisai Inc. May 1, 2025 | Consulting Fee Lenvima · Oncology | $4,890 |
| GlaxoSmithKline, LLC. Apr 2, 2025 | Consulting Fee | $800 |
| Merck Sharp & Dohme LLC Apr 2, 2025 | Consulting Fee LYNPARZA · ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $610 |
| EMD Serono Research & Development Institute, Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $709 |
| AbbVie Inc. Mar 24, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,175 |
| GlaxoSmithKline, LLC. Mar 19, 2025 | Consulting Fee | $7,200 |
| EMD Serono Research & Development Institute, Inc. Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $1,800 |
| GlaxoSmithKline, LLC. Mar 11, 2025 | Consulting Fee | $1,600 |
| GlaxoSmithKline, LLC. Feb 25, 2025 | Travel and Lodging travel to Philadelphia, PA | $64.00 |
| GlaxoSmithKline, LLC. Feb 25, 2025 | Travel and Lodging travel to Philadelphia, PA | $47.30 |
| GlaxoSmithKline, LLC. Feb 25, 2025 | Travel and Lodging travel to Philadelphia, PA | $22.00 |
| Regeneron Pharmaceuticals, Inc. Feb 7, 2025 | Consulting Fee | $2,247 |
| Regeneron Pharmaceuticals, Inc. Feb 7, 2025 | Consulting Fee | $817 |
| GlaxoSmithKline, LLC. Feb 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $939 |
| GlaxoSmithKline, LLC. Feb 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $193 |
| GlaxoSmithKline, LLC. Feb 5, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $169 |
| Genmab U.S., Inc. Jan 29, 2025 | Travel and Lodging Epkinly · Oncology · travel to Dublin, Ireland · in-kind | $3,500 |
| BioNTech SE Jan 28, 2025 | Consulting Fee | $3,575 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,750 in research payments for these studies, mostly to the institutions running them.
- Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.